Associations and outcomes according to RDW levels at AML diagnosis in patients treated with allogeneic HSCT (n = 294). Association with disease origin (A) and mutational status of genes known to associate with secondary disease (B). CIR (C) NRM (D), OS (E), and EFS (F) applying a 20.7% cut-point (high vs low). mut, mutant; sAML, secondary AML; tAML, treatment-related AML; wt, wild-type.